FDA Accepts Filing of New Estrogen-free Oral Contraceptive Slinda (drospirenone) Developed by Exeltis

FLORHAM PARK, New Jersey, November 29, 2018 /PRNewswire/ -- The pharmaceutical multinational Exeltis, with a strong position in Women's Health, has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda (4mg...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news